Arcturus Therapeutics Holdings Inc. (ARCT) SEC filings

ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/303% below fair value

$8.36−0.08 (-0.95%)

Close on Nov 13, 2026Market cap $237.62MP/E –Yield –

SEC filings

40 of Arcturus Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Sep 23, 2026	Sep 23, 2026	SEC EDGAR
Current report	8-K	Aug 25, 2026	Aug 25, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 26, 2026	Jul 2, 2026	SEC EDGAR
Current report	8-K	Jun 5, 2026	Jun 5, 2026	SEC EDGAR
Current report	8-K	May 1, 2026	May 7, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 5, 2026	Apr 24, 2026	SEC EDGAR
Current report	8-K	Mar 3, 2026	Mar 3, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 3, 2026	SEC EDGAR
Current report	8-K	Dec 11, 2025	Dec 15, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 10, 2025	Nov 10, 2025	SEC EDGAR
Current report	8-K	Oct 22, 2025	Oct 22, 2025	SEC EDGAR
Current report	8-K	Sep 26, 2025	Sep 26, 2025	SEC EDGAR
Current report	8-K	Aug 29, 2025	Aug 29, 2025	SEC EDGAR
Current report	8-K	Aug 11, 2025	Aug 11, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 11, 2025	SEC EDGAR
Current report	8-K	Jun 30, 2025	Jun 30, 2025	SEC EDGAR
Current report	8-K	Jun 6, 2025	Jun 6, 2025	SEC EDGAR
Current report	8-K	May 12, 2025	May 12, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 12, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 6, 2025	Apr 25, 2025	SEC EDGAR
Current report	8-K	Mar 6, 2025	Mar 6, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 6, 2025	SEC EDGAR
Current report	8-K	Nov 7, 2024	Nov 7, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Aug 13, 2024	Aug 13, 2024	SEC EDGAR
Current report	8-K	Aug 5, 2024	Aug 5, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 5, 2024	SEC EDGAR
Current report	8-K	Jun 19, 2024	Jun 24, 2024	SEC EDGAR
Current report	8-K	Jun 14, 2024	Jun 14, 2024	SEC EDGAR
Current report	8-K	May 8, 2024	May 8, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 8, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 14, 2024	Apr 29, 2024	SEC EDGAR
Current report	8-K	Apr 5, 2024	Apr 5, 2024	SEC EDGAR
Current report	8-K	Mar 19, 2024	Mar 19, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Arcturus Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-7 reverse split on Nov 16, 2017
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ARCT.

Compare: ARCT vs CAPR · ARCT vs QURE · ARCT vs PRQR · ARCT vs VRDN · ARCT vs WVE

Revenue growth-68.7% · median 11.4%

Operating margin-311.2% · median -661.3%

Net margin-285.9% · median -725.8%

Company	Revenue	Growth
WVE	$70.92M	–
ARCT	$30.51M	-68.7%
VRDN	$26.31M	-62.8%
QURE	$20.17M	+28.0%
PRQR	€18.36M	+11.4%
CAPR	–	–

Company

Next earnings (est.): Mar 2, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 111
Held by institutions: 87.9%
Auditor: Deloitte & Touche LLP
SEC CIK: 1768224

Advertisement
300 × 250

See a number that looks wrong?